Cargando…

PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA

Detalles Bibliográficos
Autores principales: Belada, D., Kopeckova, K., Bergua Burgues, J. M., Stevens, D., Nowakowski, G. S., Waldron-Lynch, M., Hadar, N., Weirather, J., Lässig, C., Blair, D., Dreyling, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431605/
http://dx.doi.org/10.1097/01.HS9.0000851272.68157.fc
_version_ 1784780101051744256
author Belada, D.
Kopeckova, K.
Bergua Burgues, J. M.
Stevens, D.
Nowakowski, G. S.
Waldron-Lynch, M.
Hadar, N.
Weirather, J.
Lässig, C.
Blair, D.
Dreyling, M.
author_facet Belada, D.
Kopeckova, K.
Bergua Burgues, J. M.
Stevens, D.
Nowakowski, G. S.
Waldron-Lynch, M.
Hadar, N.
Weirather, J.
Lässig, C.
Blair, D.
Dreyling, M.
author_sort Belada, D.
collection PubMed
description
format Online
Article
Text
id pubmed-9431605
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94316052022-08-31 PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA Belada, D. Kopeckova, K. Bergua Burgues, J. M. Stevens, D. Nowakowski, G. S. Waldron-Lynch, M. Hadar, N. Weirather, J. Lässig, C. Blair, D. Dreyling, M. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431605/ http://dx.doi.org/10.1097/01.HS9.0000851272.68157.fc Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Belada, D.
Kopeckova, K.
Bergua Burgues, J. M.
Stevens, D.
Nowakowski, G. S.
Waldron-Lynch, M.
Hadar, N.
Weirather, J.
Lässig, C.
Blair, D.
Dreyling, M.
PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
title PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
title_full PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
title_fullStr PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
title_full_unstemmed PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
title_short PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
title_sort pb2110: pharmacokinetics and pharmacodynamics in first-mind: a phase ib, open-label, randomized study of tafasitamab ± lenalidomide + r-chop in patients with newly diagnosed diffuse large b-cell lymphoma
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431605/
http://dx.doi.org/10.1097/01.HS9.0000851272.68157.fc
work_keys_str_mv AT beladad pb2110pharmacokineticsandpharmacodynamicsinfirstmindaphaseibopenlabelrandomizedstudyoftafasitamablenalidomiderchopinpatientswithnewlydiagnoseddiffuselargebcelllymphoma
AT kopeckovak pb2110pharmacokineticsandpharmacodynamicsinfirstmindaphaseibopenlabelrandomizedstudyoftafasitamablenalidomiderchopinpatientswithnewlydiagnoseddiffuselargebcelllymphoma
AT berguaburguesjm pb2110pharmacokineticsandpharmacodynamicsinfirstmindaphaseibopenlabelrandomizedstudyoftafasitamablenalidomiderchopinpatientswithnewlydiagnoseddiffuselargebcelllymphoma
AT stevensd pb2110pharmacokineticsandpharmacodynamicsinfirstmindaphaseibopenlabelrandomizedstudyoftafasitamablenalidomiderchopinpatientswithnewlydiagnoseddiffuselargebcelllymphoma
AT nowakowskigs pb2110pharmacokineticsandpharmacodynamicsinfirstmindaphaseibopenlabelrandomizedstudyoftafasitamablenalidomiderchopinpatientswithnewlydiagnoseddiffuselargebcelllymphoma
AT waldronlynchm pb2110pharmacokineticsandpharmacodynamicsinfirstmindaphaseibopenlabelrandomizedstudyoftafasitamablenalidomiderchopinpatientswithnewlydiagnoseddiffuselargebcelllymphoma
AT hadarn pb2110pharmacokineticsandpharmacodynamicsinfirstmindaphaseibopenlabelrandomizedstudyoftafasitamablenalidomiderchopinpatientswithnewlydiagnoseddiffuselargebcelllymphoma
AT weiratherj pb2110pharmacokineticsandpharmacodynamicsinfirstmindaphaseibopenlabelrandomizedstudyoftafasitamablenalidomiderchopinpatientswithnewlydiagnoseddiffuselargebcelllymphoma
AT lassigc pb2110pharmacokineticsandpharmacodynamicsinfirstmindaphaseibopenlabelrandomizedstudyoftafasitamablenalidomiderchopinpatientswithnewlydiagnoseddiffuselargebcelllymphoma
AT blaird pb2110pharmacokineticsandpharmacodynamicsinfirstmindaphaseibopenlabelrandomizedstudyoftafasitamablenalidomiderchopinpatientswithnewlydiagnoseddiffuselargebcelllymphoma
AT dreylingm pb2110pharmacokineticsandpharmacodynamicsinfirstmindaphaseibopenlabelrandomizedstudyoftafasitamablenalidomiderchopinpatientswithnewlydiagnoseddiffuselargebcelllymphoma